Bimonthly Survey

Please indicate if you have used resources and/or trainings from any of the following in the past 12 months.
Select all that apply

Description

Image
MATEC Logo

Join the Midwest AETC for an informative session exploring recent updates in long-acting injectable options for HIV treatment and prevention. 

Objectives

  • Review dosing and recommendations for cabotegravir, cabotegravir/rilpivirine, and lenacapavir (CAB, CAB/RPV, and LEN)
  • Discuss implementation challenges of long-acting injectables (LAIs)
  • Discuss LEN leakage and replacement protocols
  • Introduce LAI pipeline drugs for HIV treatment and prevention

Speaker

Joseph Cherabie, MD, MSc, FIDSA
Sr. Medical Director of Clinical Research and Special Programs 
Howard Brown Health

For inquiries, contact Estela Balderas at [email protected].